{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T04:24:55Z","timestamp":1754195095570},"reference-count":111,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Direct oral anticoagulants (DOACs) are considered a first-line therapy for long-term stroke prevention in patients with nonvalvular atrial fibrillation (AF) and high thromboembolic risk. The potential role of DOACs in cardiac interventional procedures is a pressing clinical question, considering the increasing number of procedures and the growing prevalence of patients in DOAC therapy. The aim of this review is to provide an update on available evidence about the clinical performance of DOACs in AF patients undergoing different interventional procedures (AF cardioversion and ablation, and percutaneous coronary and structural heart disease interventions) and to explore the possible role of DOACs as an alternative therapeutic strategy in cardiac interventional procedures among non-AF patients.<\/jats:p>","DOI":"10.1097\/fjc.0000000000000786","type":"journal-article","created":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T20:52:49Z","timestamp":1577393569000},"page":"185-199","source":"Crossref","is-referenced-by-count":10,"title":["Update on Direct Oral Anticoagulants in Atrial Fibrillation Patients Undergoing Cardiac Interventional Procedures: From Clinical Trials to Real-World Evidence"],"prefix":"10.1097","volume":"75","author":[{"given":"Enrico","family":"Melillo","sequence":"first","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreina","family":"Carbone","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Rago","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea A.","family":"Papa","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"D'. Onofrio","sequence":"additional","affiliation":[{"name":"Departmental Unit of Electrophysiology, Evaluation and Treatment of Arrhythmias, Monaldi Hospital, Naples, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Nigro","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Golino","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,3]]},"reference":[{"key":"R1-20230911","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/europace\/euw295","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"18","author":"Kirchhof","year":"2016","journal-title":"Europace."},{"key":"R2-20230911","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet."},{"key":"R3-20230911","first-page":"3961","article-title":"Efficacy and safety of dabigatran in a real-life population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry","volume":"19","author":"Russo","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"R4-20230911","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1055\/s-0037-1607436","article-title":"Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with malignancy: clinical practice experience in a single institution and literature review","volume":"44","author":"Russo","year":"2018","journal-title":"Semin Thromb Hemost."},{"key":"R5-20230911","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2459\/JCM.0000000000000744","article-title":"Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study","volume":"20","author":"Verdecchia","year":"2019","journal-title":"J Cardiovasc Med."},{"key":"R6-20230911","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.clinthera.2019.04.041","article-title":"Real-life performance of edoxaban in elderly patients with atrial fibrillation: a multicenter propensity score-matched cohort study","volume":"41","author":"Russo","year":"2019","journal-title":"Clin Ther."},{"key":"R7-20230911","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-0038-1661386","article-title":"Atrial fibrillation and malignancy: the clinical performance of non-vitamin K oral anticoagulants-A systematic review","volume":"45","author":"Russo","year":"2019","journal-title":"Semin Thromb Hemost."},{"key":"R8-20230911","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/FJC.0000000000000661","article-title":"Direct oral anticoagulants in octogenarians with atrial fibrillation: it's never too late","volume":"73","author":"Russo","year":"2019","journal-title":"J Cardiovasc Pharmacol."},{"key":"R9-20230911","first-page":"548","article-title":"New method for terminating cardiac arrhythmias. Use of synchronized capacitor discharge","volume":"182","author":"Lown","year":"1962","journal-title":"JAMA."},{"key":"R10-20230911","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0735-1097(92)90530-Z","article-title":"Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter","volume":"19","author":"Arnold","year":"1992","journal-title":"J Am Coll Cardiol."},{"key":"R11-20230911","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0002-9149(69)90068-X","article-title":"The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation","volume":"23","author":"Bjerkelund","year":"1969","journal-title":"Am J Cardiol."},{"key":"R12-20230911","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1093\/eurheartj\/ehu367","article-title":"Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation","volume":"35","author":"Cappato","year":"2014","journal-title":"Eur Heart J."},{"key":"R13-20230911","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(16)31474-X","article-title":"ENSURE-AF investigators. Edoxaban versus enoxaparin\u2013warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial","volume":"388","author":"Goette","year":"2016","journal-title":"Lancet"},{"key":"R14-20230911","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1093\/eurheartj\/ehy148","article-title":"Apixaban compared to heparin\/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial","volume":"39","author":"Ezekowitz","year":"2018","journal-title":"Eur Heart J."},{"key":"R15-20230911","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijcard.2018.04.034","article-title":"Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: a systematic review and meta-analysis","volume":"268","author":"Telles-Garcia","year":"2018","journal-title":"Int J Cardiol."},{"key":"R16-20230911","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1060028017737095","article-title":"Direct oral anticoagulants in cardioversion: a review of current evidence","volume":"52","author":"Gibson","year":"2018","journal-title":"Ann Pharmacother."},{"key":"R17-20230911","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/europace\/eux116","article-title":"Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion","volume":"20","author":"It\u00e4inen","year":"2018","journal-title":"Europace."},{"key":"R18-20230911","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/2042098616673990","article-title":"Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence","volume":"8","author":"Russo","year":"2017","journal-title":"Ther Adv Drug Saf."},{"key":"R19-20230911","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40256-019-00341-9","article-title":"Clinical performance of apixaban vs. Vitamin K antagonists in patients with atrial fibrillation undergoing direct electrical current cardioversion: a prospective propensity score-matched cohort study","volume":"19","author":"Rago","year":"2019","journal-title":"Am J Cardiovasc Drugs."},{"key":"R20-20230911","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s11239-017-1599-5","article-title":"Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study","volume":"45","author":"Russo","year":"2018","journal-title":"J Thromb Thrombolysis."},{"key":"R21-20230911","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ijcard.2016.09.022","article-title":"A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short term rivaroxaban administration: the MonaldiVert real life experience","volume":"224","author":"Russo","year":"2016","journal-title":"Int J Cardiol."},{"key":"R22-20230911","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/pace.12618","article-title":"Novel oral anticoagulants for DC cardioversion procedures: utilization and clinical outcomes compared with warfarin","volume":"38","author":"Coleman","year":"2015","journal-title":"Pacing Clin Electrophysiol."},{"key":"R23-20230911","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/europace\/eux188","article-title":"Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin","volume":"20","author":"Frederiksen","year":"2018","journal-title":"Europace."},{"key":"R24-20230911","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0735-1097(00)01178-5","article-title":"Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation","volume":"37","author":"Klein","year":"2001","journal-title":"J Am Coll Cardiol."},{"key":"R25-20230911","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijcard.2015.02.075","article-title":"Transesophageal echocardiograpy in patients with persistent atrial fibrillation undergoing electrical cardioversion on new oral anticoagulants: a multi center registry","volume":"184","author":"Stabile","year":"2015","journal-title":"Int J Cardiol."},{"key":"R26-20230911","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2017.07.048","article-title":"NOACs and atrial fibrillation: incidence and predictors of left atrial thrombus in the real world","volume":"249","author":"Bertaglia","year":"2017","journal-title":"Int J Cardiol."},{"key":"R27-20230911","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/europace\/euv294","article-title":"Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial","volume":"18","author":"Hohnloser","year":"2016","journal-title":"Europace."},{"key":"R28-20230911","first-page":"1","article-title":"Budget impact analysis of rivaroxaban vs. warfarin anticoagulation strategy for direct current cardioversion in non-valvular atrial fibrillation patients: the MonaldiVert Economic Study","volume":"66","author":"Russo","year":"2018","journal-title":"Minerva Cardioangiol."},{"key":"R29-20230911","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/ehjcvp\/pvx003","article-title":"Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry","volume":"3","author":"Papp","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"R30-20230911","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J."},{"key":"R31-20230911","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11886-010-0153-2","article-title":"Thromboembolic risk and anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation","volume":"13","author":"Viles-Gonzalez","year":"2011","journal-title":"Curr Cardiol Rep."},{"key":"R32-20230911","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.thromres.2009.11.031","article-title":"Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation","volume":"126","author":"Vazquez","year":"2010","journal-title":"Thromb Res."},{"key":"R33-20230911","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/CIRCULATIONAHA.109.921320","article-title":"Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio","volume":"121","author":"Di Biase","year":"2010","journal-title":"Circulation."},{"key":"R34-20230911","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1161\/CIRCULATIONAHA.113.006426","article-title":"Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial","volume":"129","author":"DiBiase","year":"2014","journal-title":"Circulation."},{"key":"R35-20230911","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMc1707247","article-title":"Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation","volume":"377","author":"Calkins","year":"2017","journal-title":"Engl J Med."},{"key":"R36-20230911","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/eurheartj\/ehv177","article-title":"Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation","volume":"36","author":"Cappato","year":"2015","journal-title":"Eur Heart J."},{"key":"R37-20230911","first-page":"1","article-title":"Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation","volume":"00","author":"Paulus","year":"2018","journal-title":"Eur Heart J."},{"key":"R38-20230911","first-page":"1","article-title":"Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial","volume":"00","author":"Hohnloser","year":"2019","journal-title":"Eur Heart J."},{"key":"R39-20230911","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10840-016-0221-7","article-title":"New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: a metaanalysis of continuous or interrupted new oral anticoagulants during ablation compared to interrupted or continuous warfarin","volume":"48","author":"Zhao","year":"2017","journal-title":"J Interv Card Electrophysiol."},{"key":"R40-20230911","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.amjcard.2015.12.027","article-title":"Meta-analysis of efficacy and safety of new oral anticoagulants compared with uninterrupted vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation","volume":"117","author":"Wu","year":"2016","journal-title":"Am J Cardiol."},{"key":"R41-20230911","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1161\/CIRCEP.113.000320","article-title":"Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation","volume":"6","author":"Bassiouny","year":"2013","journal-title":"Circ Arrhythm Electrophysiol."},{"key":"R42-20230911","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2013.11.039","article-title":"Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry","volume":"63","author":"Lakkireddy","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"R43-20230911","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.hrthm.2015.02.028","article-title":"Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study","volume":"12","author":"Di Biase","year":"2015","journal-title":"Heart Rhythm."},{"key":"R44-20230911","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MCA.0b013e328012a964","article-title":"Periprocedural and medium-term antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary angiography and intervention","volume":"18","author":"Rubboli","year":"2007","journal-title":"Coron Artery Dis."},{"key":"R45-20230911","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ahj.2007.09.003","article-title":"Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry","volume":"155","author":"Wang","year":"2008","journal-title":"Am Heart J."},{"key":"R46-20230911","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet."},{"key":"R47-20230911","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J."},{"key":"R48-20230911","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J."},{"key":"R49-20230911","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet."},{"key":"R50-20230911","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J."},{"key":"R51-20230911","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","article-title":"2014 ESC\/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European society of Cardiology (ESC) and the European association for cardio-thoracic surgery (EACTS)developed with the special contribution of the European association of percutaneous cardiovascular interventions (EAPCI)","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J."},{"key":"R52-20230911","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00059-017-4649-z","article-title":"Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS : the end of triple therapy?","volume":"43","author":"Fluschnik","year":"2018","journal-title":"Herz."},{"key":"R53-20230911","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","article-title":"Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates","volume":"65","author":"Valgimigli","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"R54-20230911","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1253\/circj.CJ-14-0792","article-title":"Bare-metal vs. drug-eluting stents in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"78","author":"Kiviniemi","year":"2014","journal-title":"Circ J."},{"issue":"2 suppl","key":"R55-20230911","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest."},{"key":"R56-20230911","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke."},{"key":"R57-20230911","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet."},{"key":"R58-20230911","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med."},{"key":"R59-20230911","first-page":"485","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"378","author":"Cannon","year":"2018","journal-title":"N Engl J Med."},{"key":"R60-20230911","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med."},{"key":"R61-20230911","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1056\/NEJMe1902214","article-title":"Refining antithrombotic therapy for atrial fibrillation and acute coronary syndromes or PCI","volume":"380","author":"Mehta","year":"2019","journal-title":"N Engl J Med."},{"key":"R62-20230911","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ahj.2017.10.009","article-title":"Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI trial","volume":"196","author":"Vranckx","year":"2018","journal-title":"Am Heart J."},{"key":"R63-20230911","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamacardio.2019.1880","article-title":"Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials","volume":"4","author":"Lopes","year":"2019","journal-title":"JAMA Cardiol."},{"key":"R64-20230911","first-page":"5473240","article-title":"Safety and efficacy of triple antithrombotic therapy with dabigatran versus vitamin K antagonist in atrial fibrillation patients: a Pilot study","volume":"13","author":"Russo","year":"2019","journal-title":"Biomed Res Int."},{"key":"R65-20230911","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.amjms.2019.03.009","article-title":"Use and outcomes of triple antithrombotic therapy with non-vitamin K antagonists in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"358","author":"Casamira","year":"2019","journal-title":"Am J Med Sci."},{"key":"R66-20230911","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/clc.22898","article-title":"Time trends in antithrombotic management of patients with atrial fibrillation treated with coronarystents: results from TALENT-AF (The internAtionaL stENT\u2014atrial Fibrillation study) multicenterregistry","volume":"41","author":"Potter","year":"2018","journal-title":"Clin Cardiol."},{"key":"R67-20230911","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J."},{"key":"R68-20230911","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1700456","article-title":"Surgical or transcatheter aortic-valve replacement in intermediate-risk patients","volume":"376","author":"Reardon","year":"2017","journal-title":"N Engl J Med."},{"key":"R69-20230911","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa1814052","article-title":"Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients","volume":"380","author":"Mack","year":"2019","journal-title":"N Engl J Med."},{"key":"R70-20230911","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa1816885","article-title":"Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients","volume":"380","author":"Popma","year":"2019","journal-title":"N Engl J Med."},{"key":"R71-20230911","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1161\/CIRCINTERVENTIONS.112.000124","article-title":"Atrial fibrillation and aortic stenosis: impact on clinical outcomes among patients undergoing transcatheter aortic valve implantation","volume":"6","author":"Stortecky","year":"2013","journal-title":"Circ Cardiovasc Interv."},{"key":"R72-20230911","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCINTERVENTIONS.115.002801","article-title":"Transcatheter aortic valve replacement and stroke","volume":"8","author":"Wimmer","year":"2015","journal-title":"Circ Cardiovasc Interv."},{"key":"R73-20230911","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1055\/s-0037-1615261","article-title":"Nonvitamin K antagonist oral anticoagulants use in patients with atrial fibrillation and bioprosthetic heart valves\/prior surgical valve repair: a multicenter clinical practice experience","volume":"44","author":"Russo","year":"2018","journal-title":"Semin Thromb Hemost."},{"key":"R74-20230911","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1161\/CIRCULATIONAHA.116.026714","article-title":"Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves","volume":"135","author":"Carnicelli","year":"2017","journal-title":"Circulation."},{"key":"R75-20230911","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcin.2016.10.023","article-title":"Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement","volume":"10","author":"Seeger","year":"2017","journal-title":"JACC Cardiovasc Interv."},{"key":"R76-20230911","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00392-018-1247-x","article-title":"NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation","volume":"107","author":"Geis","year":"2018","journal-title":"Clin Res Cardiol."},{"key":"R77-20230911","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jcin.2019.03.003","article-title":"Oral anticoagulant type and outcomes after transcatheter aortic valve replacement","volume":"12","author":"Jochheim","year":"2019","journal-title":"JACC Cardiovasc Interv."},{"key":"R78-20230911","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/S0140-6736(17)30757-2","article-title":"Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study","volume":"389","author":"Chakravarty","year":"2017","journal-title":"Lancet."},{"key":"R79-20230911","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ahj.2016.10.017","article-title":"Trial design: rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: rationale and design of the GALILEO study","volume":"184","author":"Windecker","year":"2017","journal-title":"Am Heart J."},{"key":"R80-20230911","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ahj.2018.03.008","article-title":"Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: the randomized ATLANTIS trial","volume":"200","author":"Collet","year":"2018","journal-title":"Am Heart J."},{"key":"R81-20230911","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ahj.2018.07.006","article-title":"Edoxaban versus standard of care and their effects on clinical outcomes in patients having undergone transcatheter aortic valve implantation in atrial fibrillation-rationale and design of the ENVISAGE-TAVI AF trial","volume":"205","author":"Van Mieghem","year":"2018","journal-title":"Am Heart J."},{"key":"R82-20230911","first-page":"103","article-title":"Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials","volume":"8","author":"Proietti","year":"2015","journal-title":"Med Devices (Auckl)."},{"key":"R83-20230911","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/pace.12058","article-title":"Does left atrial appendage closure with a cardiac plug system reduce the stroke risk in nonvalvular atrial fibrillation patients? A single-center case series","volume":"36","author":"Danna","year":"2013","journal-title":"Pacing Clin Electrophysiol."},{"key":"R84-20230911","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/CIRCULATIONAHA.112.114389","article-title":"Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (watchman left atrial appendage system for embolic protection in patients with atrial fibrillation) trial","volume":"127","author":"Reddy","year":"2013","journal-title":"Circulation."},{"key":"R85-20230911","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.jacc.2013.03.035","article-title":"Left atrial appendage closure with the watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix feasibility study with watchman left atrial appendage closure technology)","volume":"61","author":"Reddy","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"R87-20230911","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/CIRCULATIONAHA.118.035090","article-title":"Device-related thrombus after left atrial appendage closure","volume":"138","author":"Dukkipati","year":"2018","journal-title":"Circulation."},{"key":"R88-20230911","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/clc.22478","article-title":"Initial experience with novel oral anticoagulants during the first 45 Days after left atrial appendage closure with the watchman device","volume":"38","author":"B\u00f6sche","year":"2015","journal-title":"Clin Cardiol."},{"key":"R89-20230911","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.hrthm.2016.10.020","article-title":"Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device","volume":"14","author":"Enomoto","year":"2017","journal-title":"Heart Rhythm."},{"key":"R90-20230911","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jacep.2017.02.013","article-title":"Initial experience with non-vitamin K antagonist oral anticoagulants for short-term anticoagulation after left atrial appendage closure device","volume":"3","author":"Barakat","year":"2017","journal-title":"JACC Clin Electrophysiol."},{"key":"R91-20230911","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/echo.13174","article-title":"Resolution (and late recurrence) of WATCHMAN device-related thrombus following treatment with dabigatran","volume":"33","author":"Qazi","year":"2016","journal-title":"Echocardiography."},{"key":"R92-20230911","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4244\/EIJ-D-17-00042","article-title":"Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry","volume":"13","author":"Bergmann","year":"2017","journal-title":"EuroIntervention."},{"key":"R93-20230911","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1009355","article-title":"Percutaneous repair or surgery for mitral regurgitation","volume":"364","author":"Feldman","year":"2011","journal-title":"N Engl J Med."},{"key":"R94-20230911","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.117.031733","article-title":"One-year outcomes after MitraClip for functional mitral regurgitation","volume":"139","author":"Ailawadi","year":"2019","journal-title":"Circulation."},{"key":"R95-20230911","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/eurjhf\/hfs079","article-title":"MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry","volume":"14","author":"Baldus","year":"2012","journal-title":"Eur J Heart Fail."},{"key":"R96-20230911","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jacc.2013.02.094","article-title":"Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe","volume":"62","author":"Maisano","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"R97-20230911","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jcin.2014.07.024","article-title":"Extended use of percutaneous edge-to-edge mitral valve repair beyond EVEREST (endovascular valve edge-to-edge repair) criteria: 30-day and 12-month clinical and echocardiographic outcomes from the GRASP (getting reduction of mitral insufficiency by percutaneous clip implantation) registry","volume":"8","author":"Attizzani","year":"2015","journal-title":"JACC Cardiovasc Interv."},{"key":"R98-20230911","first-page":"713","article-title":"Stroke and thrombus formation appending to the MitraClip: what is the appropriate anticoagulation regimen?","volume":"22","author":"Hamm","year":"2013","journal-title":"J Heart Valve Dis."},{"key":"R99-20230911","first-page":"146","article-title":"Large atrial thrombus formation after MitraClip implantation: is anticoagulation mandatory?","volume":"20","author":"Bekeredjian","year":"2011","journal-title":"J Heart Valve Dis."},{"key":"R100-20230911","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4244\/EIJV10I2A41","article-title":"Dangerous liaison: successful percutaneous edge-to-edge mitral valve repair in patients with end-stage systolic heart failure can cause left ventricular thrombus formation","volume":"10","author":"Orban","year":"2014","journal-title":"EuroIntervention."},{"key":"R101-20230911","first-page":"1","article-title":"Temporary oral anticoagulation after MitraClip\u2014a strategy to lower the incidence of post-procedural stroke?","volume":"16","author":"Geis","year":"2019","journal-title":"Acta Cardiol."},{"key":"R102-20230911","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jcin.2018.11.009","article-title":"Apixaban after percutaneous edge-to-edge mitral valve repair in patients with maintained sinus rhythm","volume":"12","author":"Seeger","year":"2019","journal-title":"JACC Cardiovasc Interv."},{"key":"R103-20230911","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1610057","article-title":"Long-term outcomes of patent foramen ovale closure or medical therapy after stroke","volume":"377","author":"Saver","year":"2017","journal-title":"N Engl J Med."},{"key":"R104-20230911","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1707404","article-title":"Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke","volume":"377","author":"S\u00f8ndergaard","year":"2017","journal-title":"N Engl J Med."},{"key":"R105-20230911","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","article-title":"Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke","volume":"377","author":"Mas","year":"2017","journal-title":"N Engl J Med."},{"key":"R106-20230911","first-page":"2915","article-title":"ESC Guidelines for the management of grown-up congenital heart disease","volume":"31","author":"Baumgartner","year":"2010","journal-title":"Eur Heart J."},{"key":"R107-20230911","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.amjcard.2003.10.036","article-title":"Incidence of thrombus formation on the CardioSEAL and the Amplatzer interatrial closure devices","volume":"93","author":"Anzai","year":"2004","journal-title":"Am J Cardiol."},{"key":"R108-20230911","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/ccd.24875","article-title":"Short and long term complications of device closure of atrial septal defect and patent foramen ovale: meta-analysis of 28,142 patients from 203 studies","volume":"82","author":"Abaci","year":"2013","journal-title":"Catheter Cardiovasc Interv."},{"key":"R109-20230911","doi-asserted-by":"crossref","first-page":"e008356","DOI":"10.1161\/JAHA.117.008356","article-title":"Closure, anticoagulation, or antiplatelet therapy for cryptogenic stroke with patent foramen ovale: systematic review of randomized trials, sequential meta-analysis, and new insights from the CLOSE study","volume":"7","author":"Turc","year":"2018","journal-title":"J Am Heart Assoc."},{"key":"R110-20230911","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fcvm.2019.00075","article-title":"Antithrombotic\/antiplatelet treatment in transcatheter structural cardiac interventions\u2014PFO\/ASD\/LAA occluder and InteratrialShunt devices","volume":"6","author":"Olasinska-Wisniewska","year":"2019","journal-title":"Front Cardiovasc Med."},{"key":"R111-20230911","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.4244\/EIJ-D-18-00622","article-title":"European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism","volume":"14","author":"Pristipino","year":"2019","journal-title":"EuroIntervention."},{"key":"R112-20230911","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","article-title":"Rivaroxaban for stroke prevention after embolic stroke of undetermined Source","volume":"378","author":"Hart","year":"2018","journal-title":"N Engl J Med."}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FJC.0000000000000786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T02:01:44Z","timestamp":1694397704000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FJC.0000000000000786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":111,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0000000000000786","relation":{},"ISSN":["0160-2446"],"issn-type":[{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}